Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Thu, 29.06.2023
Mainz BioMed N.V.
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programs
BERKELEY, US – MAINZ, Germany – June 29, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it [ … ]
Thu, 29.06.2023
Mainz BioMed N.V.
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programs
BERKELEY, US – MAINZ, Germany – June 29, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it [ … ]
Wed, 28.06.2023
Mainz BioMed N.V.
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología
BERKELEY, US – MAINZ, Germany – June 28, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the [ … ]
Wed, 28.06.2023
Mainz BioMed N.V.
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología
BERKELEY, US – MAINZ, Germany – June 28, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the [ … ]
Tue, 20.06.2023
Mainz BioMed N.V.
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
ColoAlert® will be offered to an addressable market of 6 million patients through 15 laboratories.
BERKELEY, US – MAINZ, Germany – June 20, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early [ … ]
Tue, 20.06.2023
Mainz BioMed N.V.
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
ColoAlert® will be offered to an addressable market of 6 million patients through 15 laboratories.
BERKELEY, US – MAINZ, Germany – June 20, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early [ … ]
Wed, 31.05.2023
Mainz BioMed N.V.
Mainz Biomed Expands Commercial Footprint into Poland
Total addressable market in Poland is estimated at 21 million patients
BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the est [ … ]
Wed, 31.05.2023
Mainz BioMed N.V.
Mainz Biomed Expands Commercial Footprint into Poland
Total addressable market in Poland is estimated at 21 million patients
BERKELEY, US – MAINZ, Germany – May 31, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the est [ … ]
Wed, 24.05.2023
Mainz BioMed N.V.
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöller-Kipper
Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient
BERKELEY, US – MAINZ, Germany – May 24, 2023 —Mainz Biomed NV (NASDAQ:MYNZ) (“Ma [ … ]
Wed, 24.05.2023
Mainz BioMed N.V.
Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöller-Kipper
Employees found the online patient portal, through which they ordered the ColoAlert® test, easy-to-use and convenient
BERKELEY, US – MAINZ, Germany – May 24, 2023 —Mainz Biomed NV (NASDAQ:MYNZ) (“Ma [ … ]